Dosing & Uses
Dosage Forms & Strengths
capsule
- 250mg
Chronic Pheochromocytoma
Indicated for treatment of patients with pheochromocytoma for: 1) preoperative preparation for surgery; 2) management when surgery is contraindicated; and 3) chronic treatment with malignant pheochromocytoma
Initial: 250 mg PO q6hr; may increase by 250-500 mg/day, not to exceed 4 g/day
Maintenance: Typically 2-3 g/day divided q6hr
Dosing Considerations
Not indicated for essential hypertension
When used for preoperative preparation, the optimally effective dose should be given for at least 5-7 days
Psychosis (Orphan)
Treatment of velocardiofacial syndrome associated psychosis
Orphan indication sponsor
- Aton Pharma, Inc; 3150 Brunswick Place; Lawrenceville, NJ 08648
Dosage Forms & Strengths
capsule
- 250mg
Chronic Pheochromocytoma
Indicated for treatment of patients with pheochromocytoma for: 1) preoperative preparation for surgery; 2) management when surgery is contraindicated; and 3) chronic treatment with malignant pheochromocytoma
<12 years: Safety and efficacy not established
≥12 years
- Initial: 250 mg PO q6hr; may increase by 250-500 mg/day, not to exceed 4 g/day
- Maintenance: Typically 2-3 g/day divided q6hr
Dosing Considerations
Not indicated for essential hypertension
When used for preoperative preparation, the optimally effective dose should be given for at least 5-7 days
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Sedation (>20%)
1-10%
Diarrhea (10%)
Exrapyramidal Symptoms (10%)
Frequency Not Defined
Fatigue
Headache
Psychic Disturbances
Galactorrhea
Sexual dysfunction
Nausea
Vomiting
Xerostomia
Nasal stuffiness
Dysuria
Crystalluria
Warnings
Contraindications
Hypersensitivity to metyrosine
Cautions
Additive sedative effects w/ alcohol and other CNS depressants
Take enough fluid to prevent crystalluria
Use caution in hepatic or renal impairment
Not recommended for essential HTN
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted into breast milk, use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inhibits synthesis of endogenous catecholamines by inhibiting tyrosine hydroxylase
Pharmacokinetics
Half-Life: 3-4 hr
Bioavailability: Well absorbed
Metabolism: liver
Metabolite: Catechol metabolites (inactive)
Excretion: urine 53-88%
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
